Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

IL7RsignaTHER

Financiado

Participar

Antibody based IL 7R targeted therapies

Acute lymphoblastic leukemia (ALL), a highly aggressive hematological cancer, is the most frequent childhood malignancy and the second most common acute leukemia in adults. The use of risk-adjusted multi-agent intensive chemothera... ver más

31/12/2021

iMM

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANT... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-12-31

ERC-2019-POC: ERC Proof of Concept Grant

I+D

Cerrada hace 5 años

0% 100% 100%

2 Participantes

iMM

150.00K€ | Lider

SCHNEIDER ELECTRIC ESPAÑA

322.22K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Últimas noticias

18-12-2024: TORRES QUEVEDO 2024 Se abre la línea de ayuda pública: Ayudas para contratos Torres Quevedo (PTQ) 2024

18-12-2024: REDES En las últimas 48 horas el Organismo REDES ha otorgado 2181 concesiones

18-12-2024: SETEID En las últimas 48 horas el Organismo SETEID ha otorgado 1 concesiones

Duración del proyecto: 29 meses Fecha Inicio: 2019-07-30
Fecha Fin: 2021-12-31

Líder del proyecto

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANT... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Acute lymphoblastic leukemia (ALL), a highly aggressive hematological cancer, is the most frequent childhood malignancy and the second most common acute leukemia in adults. The use of risk-adjusted multi-agent intensive chemotherapy has led to a remarkable improvement in treatment outcome of pediatric cases, with more than 80% of children with ALL being alive and disease-free at 5 years. However, a significant number of relapses still occur, whose prognosis is dismal, and the intensive regimens used are often associated with long-term, severe complications. In adults, the scenario is considerably worse: only 30–40% of the cases achieve long-term remission. Therefore, there is an obvious unmet need, and a major challenge, to develop novel, more efficient therapeutic strategies that specifically target the leukemic cells, minimize the detrimental side effects associated with conventional therapies and improve overall treatment outcome. Based on exciting and robust preliminary data from our ERC Consolidator Grant IL7sigNETure (CoG-648455), we now propose to explore the dependence of ALL cells on IL-7/IL-7R-mediated signaling and the broad expression of IL-7R on the surface of ALL cells to develop and commercialize novel monoclonal antibody-based biopharmaceuticals that we will generate targeting the IL-7/IL-7R axis for treatment of this malignancy. Our innovative therapeutic strategies have significant market potential that extends beyond ALL. Other possible indications include other lymphoid malignancies (Hodgkin's lymphoma, peripheral T-cell lymphoma, chronic lymphocytic leukemia), solid cancers with ectopic expression of IL-7R (including melanoma, breast, lung, bladder and colorectal cancer, or glioblastoma), and autoimmune and chronic inflammatory diseases (diabetes, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease) in which the IL-7/IL-7R axis plays a pathological role.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores